Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

By L. Butler, D. Agus, H. Scher, B. Higgins, Adam Rose, C. Cordon-Cardo, H. Thaler, R. Rifkind, PA Marks, V. Richon. Cancer Research, 2000

618 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Discovery and development of SAHA as an anticancer agent (2007, background): “The intraperitoneal administration of SAHA daily for 21 days completely inhibited tumor cell growth at doses that had no detectable toxic effects on normal cells (Butler et al., 2000).”
Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice (2003, unknown): “Because HDAC inhibitors induce growth arrest in cell proliferation models, HDAC inhibitors are currently under development as anti-cancer drugs (Butler et al., 2000; Richon et al., 2000; Vigushin and Coombes, 2002).”
Histone deacetylase inhibitors: molecular mechanisms of action (2007, background): “In preclinical studies, resistance to HDACi-induced transformed cell death was observed in human bladder carcinoma cells (T24) and prostate cancer cells (PC3) (Butler et al., 2000; Richon et al., 2000; Xu et al., 2006).”